SCHEMBL2802799

SCHEMBL2802799

CCS(=O)(=O)NC(=O)c1cnn2c(Nc3cccc(F)c3C)c(C(=O)N3CCC(c4ccccc4)CC3)cnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
EGLN1 Q9GZT9 1/20 0.39
KMT2A Q03164 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
SPR P35270 2/20 0.36
FASN P49327 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
GLA P06280 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SCN9A Q15858 2/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
TPSAB1 Q15661 1/20 0.35
SIRT5 Q9NXA8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801762 0.92 EGLN1 (0.39) ALDH1A1EGLN1KMT2AKDM4EMEN1
SCHEMBL2801637 0.92 SIRT5 (0.41) ALDH1A1EGLN1LMNASPRFASN
SCHEMBL2799916 0.91 EGLN1 (0.39) ALDH1A1EGLN1KMT2AKDM4EMEN1
SCHEMBL2799384 0.91 NPC1 (0.38) ALDH1A1EGLN1KMT2ASPRFASN
SCHEMBL2803213 0.90 NPC1 (0.40) ALDH1A1KMT2ASPRFASNNPC1
SCHEMBL2800842 0.90 ALDH1A1 (0.38) ALDH1A1EGLN1KMT2AKDM4ESPR
SCHEMBL2800090 0.89 ALDH1A1 (0.42) ALDH1A1EGLN1KMT2AKDM4EMEN1
SCHEMBL2803776 0.89 SPR (0.38) ALDH1A1KMT2AKDM4ELMNASPR
SCHEMBL2801510 0.88 EGLN1 (0.38) ALDH1A1EGLN1SPRFASNSIRT5
SCHEMBL2800033 0.88 ALDH1A1 (0.43) ALDH1A1EGLN1KMT2ASPRFASN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 ALDH1A1 243/4885EGLN1 1967/4885KMT2A 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.